Bringing Liraglutide to Market: A CER Case Study

por Oderda, Gary, Sifford-Wilson, S. Monet
Publicado 2012

Introduction

por Brixner, Diana I., Oderda, Gary
Publicado 2012

Comparative Effectiveness Research (CER): A Summary of AHRQ’s CER on Therapies for Rheumatoid Arthritis

por Oderda, Gary M., Balfe, Lisa M.
Publicado 2011

Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic...

por Wu, Ning, Yu, Xia, Greene, Mallik, Oderda, Gary
Publicado 2014

Payer perceptions on the use of economic models in oncology decision making

por Biskupiak, Joseph, Oderda, Gary, Brixner, Diana, Burgoyne, Douglas, Arondekar, Bhakti, Niyazov, Alexander
Publicado 2021

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making

por Brixner, Diana I., Oderda, Gary, Mohr, Penny, Dubois, Robert W., Cannon, H. Eric
Publicado 2012

Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis

por Agarwal, Sandeep K., Farheen, Kiran, Oderda, Gary M., Engen, Carrie, Balfe, Lisa M.
Publicado 2011

Systematic review on quality control for drug management programs: Is quality reported in the literature?

por Holtorf, Anke-Peggy, McAdam-Marx, Carrie, Schaaf, David, Eng, Benjamin, Oderda, Gary
Publicado 2009

Payer perceptions of the use of real-world evidence in oncology-based decision making

por Brixner, Diana, Biskupiak, Joseph, Oderda, Gary, Burgoyne, Douglas, Malone, Daniel C, Arondekar, Bhakti, Niyazov, Alexander
Publicado 2021

Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center

por LaFleur, Joanne, McBeth, Carrieann, Gunning, Karen, Oderda, Lynda, Steinvoort, Carin, Oderda, Gary M.
Publicado 2006

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

por Rochau, Ursula, Kluibenschaedl, Martina, Stenehjem, David, Kuan-Ling, Kuo, Radich, Jerald, Oderda, Gary, Brixner, Diana, Siebert, Uwe
Publicado 2015

“This Drug May Work, But Is It Worth the Cost?” Can Comparative Effectiveness Research Help Tame Rising Health Care Costs?

por Brixner, Diana I., Watkins, John B., Oderda, Gary, Sifford-Wilson, S. Monet, Biskupiak, Joseph E., Dunn, Jeffrey D., Holtorf, Anke-Peggy
Publicado 2012

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advan...

por Mistry, Rohit, May, Jessica R., Suri, Gaurav, Young, Kate, Brixner, Diana, Oderda, Gary, Biskupiak, Joseph, Tang, Derek, Bhattacharyya, Subrata, Mishra, Dinesh, Bhattacharyya, Devarshi, Dalal, Anand A.
Publicado 2018

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center

por Stenehjem, David D., Au, Trang H., Ngorsuraches, Surachat, Ma, Junjie, Bauer, Hillevi, Wanishayakorn, Tanatape, Nelson, Ryan S., Pfeiffer, Constance M., Schwartz, Joshua, Korytowsky, Beata, Oderda, Gary, Brixner, Diana I.
Publicado 2019